Lundbeck has gained ODD from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to treat multiple system ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

International pharmaceutical company Lundbeck deployed a secret agent to the Gaza Strip in addition to hiring a missing-persons expert when campaigning for the release of its employee, former ...

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...

(Bloomberg) -- H. Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug ...

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its ...

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...